Centro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  3. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  4. NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma

    Journal for immunotherapy of cancer, Vol. 12, Núm. 8

  5. Radiotherapy protocols for mouse cancer model

    Methods in Cell Biology (Academic Press Inc.), pp. 99-113

2023

  1. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  2. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  3. Methods to assess radiation induced abscopal responses in mice

    Methods in Cell Biology (Academic Press Inc.), pp. 81-92

2022

  1. Charting roadmaps towards novel and safe synergistic immunotherapy combinations

    Nature Cancer, Vol. 3, Núm. 6, pp. 665-680

  2. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  3. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  2. Consolidating radiotherapy with immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 20

  3. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

    European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280

  4. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8

    Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201

  5. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Cellular cytotoxicity is a form of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  3. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

    Nature Immunology, Vol. 21, Núm. 2, pp. 120-134

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15